Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 6th Conference on Retroviruses and Opportunistic Infections
Abstract No. 604: BMS-232632: Single and Multiple Oral Dose Safety and Pharmacokinetic Study in Healthy Volunteers

February 3, 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Phase I data (first in man study) was presented evaluating the pharmacokinetics of five different doses (once daily doses of either 100mg, 300, 600, 900, 1200) in 40 healthy volunteers, in a double-blind, placebo-controlled and randomized study. In each dose group 6 were given drug and 2 were given placebo. Bioavailabilty of a capsule formulation averaged 68% relative to that of an oral solution and was tolerated well. A few cases of diarrhea and GI discomfort were reported. Isolated asymptomatic increases in serum bilirubin were seen mostly in the groups receiving 500 and 600 mg daily. The group of subjects taking doses above 300mg daily demonstrated serum concentrations of drug that were above the EC50 for HIV for more than a 24 hour period, distinguishing this agent for once daily dosing. To date, dose ranges of 200-600 mg daily have been evaluated over a two week period, and treatment-related adverse events were mild, reversible and consisted of asymptomatic elevations of unconjugated bilirubin in one third of patients. Plans are being made to study this drug further in larger human trials.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract: BMS-232632: Single and Multiple Oral Dose Safety and Pharmacokinetic Study in Healthy Volunteers
Authored by: E.M. O'Mara, J. Smith, S.J. Olsen, T. Tanner, A.E. Schuster, and S. Kaul

See Also
More on HIV Medications
More News and Research on Atazanavir (Reyataz)
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement